Information Provided By: 
Fly News Breaks for September 19, 2016
STJ, JNJ, ALR, ABT
Sep 19, 2016 | 05:47 EDT
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
News For ABT;ALR;JNJ;STJ From the Last 2 Days
ABT
Apr 16, 2024 | 13:13 EDT
JNJ
Apr 16, 2024 | 12:01 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
JNJ
Apr 16, 2024 | 11:49 EDT
H.C. Wainwright notes that Legend Biotech (LEGN) partner Janssen, a division of Johnson & Johnson (JNJ), reported Q1 aggregate revenues for Carvykti that implied a 1% quarter-over-quarter contraction following 5% quarter-over-quarter growth recorded from Q3 to Q4. However, the flat sales in Q were "not alarming to us" as the firm expects a return to growth, with substantial growth in the second half of 2024 compared to the first half, says the analyst, who reiterates a Buy rating and $87 price target on Legend shares.
JNJ
Apr 16, 2024 | 09:30 EDT
Says has financial flexibility to consider multiple types of transactions.
JNJ
Apr 16, 2024 | 08:58 EDT
JNJ
Apr 16, 2024 | 08:52 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. HIGHER - Macatawa... To see the rest of the story go to thefly.com. See Story Here
JNJ
Apr 16, 2024 | 06:43 EDT
JNJ
Apr 16, 2024 | 06:25 EDT
JNJ
Apr 16, 2024 | 06:23 EDT
JNJ
Apr 16, 2024 | 06:20 EDT
Reports Q1 revenue $21.4B, consensus $21.4B. "Johnson & Johnson's solid first quarter performance reflects our sharpened focus and the progress in our portfolio and pipeline," said Joaquin Duato, Chairman and Chief Executive Officer. "Our impact across the full spectrum of healthcare is unique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse."
JNJ
Apr 15, 2024 | 12:57 EDT
Notable companies reporting before tomorrow's open, with earnings consensus, include UnitedHealth (UNH), consensus $6.21... Johnson & Johnson (JNJ), consensus $2.47... Bank of America (BAC), consensus 72c... Morgan Stanley (MS), consensus $1.66... PNC Financial (PNC), consensus $3.02... BNY Mellon (BK), consensus $1.19.
JNJ
Apr 15, 2024 | 06:28 EDT
JNJ
Apr 15, 2024 | 06:08 EDT
